Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aslan Pharmaceuticals Ltd ADR (ASLN)

Aslan Pharmaceuticals Ltd ADR (ASLN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study

The FDA lifts the partial clinical hold on DBV Technologies' (DVBT) phase III VITESSE study of a modified Viaskin Peanut patch in peanut-allergic children aged four to seven years. Stock rises.

ADAP : 1.7200 (-0.58%)
DBVT : 1.3900 (-4.14%)
ASLN : 0.7229 (-2.60%)
IMCR : 63.45 (-0.11%)
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly

ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.

LLY : 338.70 (+2.42%)
PRQR : 3.00 (+5.26%)
ASLN : 0.7229 (-2.60%)
IMCR : 63.45 (-0.11%)
ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study

ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter's elranatamab in multiple myeloma. Stock up in after-hours trading.

PFE : 44.12 (-0.50%)
ASLN : 0.7229 (-2.60%)
ORIC : 5.73 (-4.98%)
IMCR : 63.45 (-0.11%)
Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC

The FDA bestows a Breakthrough Therapy designation to Mirati's (MRTX) Krazati (adagrasib) for treating patients with advanced, KRAS-mutated colorectal cancer.

MRK : 102.77 (-0.67%)
AMGN : 244.12 (-0.98%)
MRTX : 52.17 (-3.85%)
ASLN : 0.7229 (-2.60%)
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis

The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis.

REGN : 778.00 (+3.57%)
SNY : 46.05 (-2.52%)
ASLN : 0.7229 (-2.60%)
IPHA : 3.47 (+1.90%)
Apellis (APLS) Files MAA for Pegcetacoplan in GA in Europe

Apellis (APLS) submits a marketing authorization application for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration to the European Medicines Agency.

AZN : 63.59 (+0.70%)
APLS : 56.40 (-0.58%)
ASLN : 0.7229 (-2.60%)
IMCR : 63.45 (-0.11%)
Ultragenyx's (RARE) Portfolio of Marketed Drugs Aids Growth

Ultragenyx's (RARE) marketed drugs, which are approved for various indications, are driving the top line. The company also has a strong pipeline. However, pipeline setbacks remain concerning.

REGN : 778.00 (+3.57%)
RARE : 46.57 (-1.63%)
ASLN : 0.7229 (-2.60%)
IMCR : 63.45 (-0.11%)
AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie

AbCellera (ABCL) inks a strategic collaboration with AbbVie to develop new antibody therapies across multiple indications. ABCL shares rise.

ABBV : 145.80 (+0.66%)
ASLN : 0.7229 (-2.60%)
ABCL : 11.28 (+2.45%)
RLYB : 6.61 (-2.55%)
Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474

Kymera (KYMR) posts positive data from a phase I study on KT-474 for treating patients with hidradenitis suppurativa and atopic dermatitis. Sanofi to advance KT-474 in phase II study.

SNY : 46.05 (-2.52%)
AGLE : 0.5050 (+3.06%)
ASLN : 0.7229 (-2.60%)
KYMR : 37.60 (-2.97%)
Sanofi's (SNY) Dupixent Gets Europe Nod for Prurigo Nodularis

The EC approves Sanofi (SNY) and its partner Regeneron's Dupixent for the treatment of adult patients with prurigo nodularis.

REGN : 778.00 (+3.57%)
SNY : 46.05 (-2.52%)
AGLE : 0.5050 (+3.06%)
ASLN : 0.7229 (-2.60%)

Barchart Exclusives

Weak Chip Demand Leads to a Glut of Memory Chips
The $160 billion memory-chip sector is suffering from one of its worst routs due to a glut of chips sitting in warehouses, plunging customer orders, and a sharp decline in product prices. The sector has seen a sharp reversal from the pandemic sales surge, which was fueled by strong demand... Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar